Press releases

Invitation to presentation of BioArctic’s Interim Report for the period January – June 2018 on August 23, 2018

August 14, 2018

Stockholm, Sweden, August 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – June 2018 ...

BioArctic obtains exclusive rights to develop antibody treatments for Alzheimer’s disease from a research project jointly owned with Eisai

August 7, 2018

Stockholm, Sweden, August 7, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has in collaboration with Eisai identified a completely new biological target, which provides ...

BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer’s disease presented at AAIC 2018

July 25, 2018

  Stockholm, Sweden, July 25, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced on July 6 the positive topline results from the clinical ...

BioArctic: Late breaking Phase 2b study results of BAN2401 in Alzheimer’s disease will be webcast live from AAIC 2018 by Eisai

July 18, 2018

Stockholm, Sweden, July 18, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B). As previously announced, the BAN2401 Phase 2b clinical study results will be presented ...

BioArctic receives regulatory approval in Finland for a clinical study in patients with Complete Spinal Cord Injury

July 10, 2018

Stockholm, Sweden, July 10, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by Fimea, the Finnish Medicines ...

BioArctic Announces Acceptance of BAN2401 Phase 2b Results for Oral Presentation at the AAIC 2018

July 10, 2018

Stockholm, Sweden, July 10, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces today the results of the BAN2401 Phase 2b clinical study (ClinicalTrials.gov identifier ...

BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer’s Disease

July 6, 2018

The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in early Alzheimer’s disease demonstrated statistically significant and dose-dependent slowing in clinical ...

BioArctic announces changes in the Management Team effective September 1, 2018

June 27, 2018

Stockholm, Sweden, June 27, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that professor Lars Lannfelt resumes his employment in the company as ...

BioArctic receives this year’s SwedenBIO Award

May 16, 2018

Stockholm, Sweden, May 16, 2018 – BioArctic AB today received the SwedenBIO Award 2018. The prize is awarded to a company that has distinguished itself by ...

Report from the Annual General Meeting in BioArctic AB (publ)

May 15, 2018

BioArctic AB (publ) held its Annual General Meeting on Tuesday May 15, 2018. The following resolutions were adopted:

BioArctic extends the research collaboration with Uppsala University regarding new antibody technology

May 14, 2018

Stockholm, Sweden, May 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has signed an extended research collaboration agreement with ...

Interim Report January – March 2018

April 26, 2018

Continued progress of the project portfolio  January - March 2018 Net sales for the period amounted to SEK 52.3 million (26.2)  Operating profit amounted to SEK ...

Inclusion completed of patients with complete spinal cord injury in the first panel of BioArctic’s ongoing study

April 25, 2018

Stockholm, Sweden, April 25, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the inclusion of patients with complete spinal cord injury in ...

BioArctic publishes the Annual Report for 2017

April 24, 2018

Stockholm, Sweden, April 24, 2018 – BioArctic AB (publ.) (Nasdaq Stockholm: BIOA B) announced today that the Annual Report for the 2017 fiscal year has ...

NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)

April 13, 2018

The shareholders in BioArctic AB (publ), corporate identity number 556601-2679, (”the Company”) are hereby summoned to the Annual General Meeting to be held on Tuesday, ...

Invitation to presentation of BioArctic’s Interim Report January – March 2018 on April 26, 2018

April 12, 2018

Stockholm, Sweden, April 12, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2018 ...

BioArctic receives regulatory approval in Norway for a clinical study in patients with Complete Spinal Cord Injury

March 21, 2018

Stockholm, Sweden, March 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by the Norwegian Medicines Agency ...

BioArctic receives patent protection in Japan for a medical device for treatment of patients with Complete Spinal Cord Injury

March 19, 2018

Stockholm, Sweden, March 19, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Japanese Patent Office (JPO) issued a notification to grant ...

BioArctic receives regulatory approval in Estonia for a clinical study in patients with Complete Spinal Cord Injury

February 21, 2018

Stockholm, Sweden, February 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by the Estonian State Agency ...

Full Year Report January – December 2017

February 20, 2018

Successful IPO and continued positive result for BioArctic. October – December 2017. Net sales for the period amounted to SEK 51.0 million (94.4). Operating profit amounted ...

Invitation to presentation of BioArctic’s Full Year Report 2017 on February 20, 2018

February 5, 2018

Stockholm, Sweden, February 5, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report 2017 for the period January – ...

BioArctic receives US patent protection for a method with a medical device for treatment of patients with Complete Spinal Cord Injury

February 2, 2018

Stockholm, Sweden, February 2, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) published an Issue ...

BioArctic announces that the Phase 2b study of BAN2401 in early Alzheimer´s Disease continues toward 18 month endpoint

December 21, 2017

Criteria for success at 12 month interim analysis of ADCOMS not met Study to remain blinded per protocol until final readout of comprehensive 18 month data

BioArctic presents Nomination Committee and publishes financial calendar 2018

November 9, 2017

Stockholm, Sweden, November 9, 2017 – According to the resolution of the Annual General Meeting in BioArctic AB (publ) on May 31, 2017 the members of ...

Interim Report January – September 2017

November 8, 2017

BioArctic listed on Nasdaq Stockholm Mid Cap. July - September 2017- Net sales for the period amounted to SEK 31.5 million (1.2). Operating profit amounted to SEK ...

EXERCISE OF OVER-ALLOTMENT OPTION AND END OF THE STABILIZATION PERIOD

November 6, 2017

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...

Invitation to presentation of BioArctic’s Interim Report January – September 2017 on November 8

November 3, 2017

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) publishes the company’s Interim Report for the period January – September 2017 on November 8, 2017 at 08:00 a.m. ...

Change in the number of shares and votes in BioArctic AB (publ)

October 31, 2017

Stockholm, Sweden, October 31, 2017 – BioArctic AB (publ) (“BioArctic” or the “Company” ) today announced that the number of shares and votes in BioArctic has ...

Stabilization notice

October 20, 2017

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...

BioArctic’s patent for its product candidate antibody BAN0805, for Parkinson’s disease, is now granted in Europe

October 13, 2017

Stockholm, Sweden, October 13, 2017 – BioArctic AB (publ) (Nasdaq Stockholm:BIOA B) today announced that the European Patent Office (EPO) has decided to grant a European ...

Trading in BioArctic’s B-shares commences today on Nasdaq Stockholm

October 12, 2017

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...

BioArctic AB publishes prospectus for initial public offering on Nasdaq Stockholm

September 29, 2017

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...

BioArctic AB intends to list on Nasdaq Stockholm

September 13, 2017

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...

BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research

September 20, 2016

BioArctic announced that it entered into a strategically important collaboration with AbbVie (NYSE: ABBV), a global biopharmaceutical company, to develop and commercialize BioArctic’s portfolio of antibodies ...

Pharmaceutical study starts in Sweden with BAN2401 in early Alzheimer patients

May 12, 2014

BioArctic Neuroscience AB today announced that the first patient in Sweden has been treated with BAN2401 in a clinical study aimed at patients with an early ...

BioArctic Neuroscience and Elos Medtech start collaboration on new treatment for spinal cord injuries

October 19, 2010

The Swedish biotech company BioArctic Neuroscience and the medtech company Elos Medtech have today signed a cooperation agreement for a new treatment of spinal cord injuries.

Drug Candidate Receives Orphan Drug Designation

April 22, 2010

The text below is a translation of a Swedish press release. BioArctic Neuroscience develops treatments to help victims of spinal cord injury. The European Medicines Agency ...

BioArctic Neuroscience and Swenora Biotech Enter Into Exclusive Licensing Agreement

June 26, 2008

Today the Swedish biotech companies BioArctic Neuroscience and Swenora Biotech have entered into an exclusive licensing agreement for a novel treatment of Spinal Cord Injury Treatment. ...